CDXS
Price
$1.36
Change
-$1.32 (-49.25%)
Updated
Feb 3 closing price
Capitalization
123.29M
22 days until earnings call
Intraday BUY SELL Signals
VCEL
Price
$37.10
Change
+$4.33 (+13.21%)
Updated
Feb 3 closing price
Capitalization
1.87B
22 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CDXS vs VCEL

Header iconCDXS vs VCEL Comparison
Open Charts CDXS vs VCELBanner chart's image
Codexis
Price$1.36
Change-$1.32 (-49.25%)
Volume$983.92K
Capitalization123.29M
Vericel
Price$37.10
Change+$4.33 (+13.21%)
Volume$438.12K
Capitalization1.87B
CDXS vs VCEL Comparison Chart in %
View a ticker or compare two or three
VS
CDXS vs. VCEL commentary
Feb 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CDXS is a Hold and VCEL is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 04, 2026
Stock price -- (CDXS: $1.36 vs. VCEL: $37.10)
Brand notoriety: CDXS and VCEL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CDXS: 94% vs. VCEL: 78%
Market capitalization -- CDXS: $123.29M vs. VCEL: $1.87B
CDXS [@Biotechnology] is valued at $123.29M. VCEL’s [@Biotechnology] market capitalization is $1.87B. The market cap for tickers in the [@Biotechnology] industry ranges from $118.13B to $0. The average market capitalization across the [@Biotechnology] industry is $2.22B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CDXS’s FA Score shows that 1 FA rating(s) are green whileVCEL’s FA Score has 0 green FA rating(s).

  • CDXS’s FA Score: 1 green, 4 red.
  • VCEL’s FA Score: 0 green, 5 red.
According to our system of comparison, CDXS is a better buy in the long-term than VCEL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CDXS’s TA Score shows that 4 TA indicator(s) are bullish while VCEL’s TA Score has 4 bullish TA indicator(s).

  • CDXS’s TA Score: 4 bullish, 6 bearish.
  • VCEL’s TA Score: 4 bullish, 7 bearish.
According to our system of comparison, CDXS is a better buy in the short-term than VCEL.

Price Growth

CDXS (@Biotechnology) experienced а -4.90% price change this week, while VCEL (@Biotechnology) price change was +1.42% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -4.22%. For the same industry, the average monthly price growth was +3.03%, and the average quarterly price growth was +35.17%.

Reported Earning Dates

CDXS is expected to report earnings on Feb 26, 2026.

VCEL is expected to report earnings on Feb 26, 2026.

Industries' Descriptions

@Biotechnology (-4.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VCEL($1.87B) has a higher market cap than CDXS($123M). VCEL YTD gains are higher at: 3.027 vs. CDXS (-16.564). VCEL has higher annual earnings (EBITDA): 23.8M vs. CDXS (-55.32M). VCEL has more cash in the bank: 135M vs. CDXS (58.7M). CDXS has less debt than VCEL: CDXS (68.6M) vs VCEL (98M). VCEL has higher revenues than CDXS: VCEL (259M) vs CDXS (52.9M).
CDXSVCELCDXS / VCEL
Capitalization123M1.87B7%
EBITDA-55.32M23.8M-232%
Gain YTD-16.5643.027-547%
P/E RatioN/A142.54-
Revenue52.9M259M20%
Total Cash58.7M135M43%
Total Debt68.6M98M70%
FUNDAMENTALS RATINGS
CDXS vs VCEL: Fundamental Ratings
CDXS
VCEL
OUTLOOK RATING
1..100
5574
VALUATION
overvalued / fair valued / undervalued
1..100
28
Undervalued
92
Overvalued
PROFIT vs RISK RATING
1..100
10090
SMR RATING
1..100
9985
PRICE GROWTH RATING
1..100
9060
P/E GROWTH RATING
1..100
10099
SEASONALITY SCORE
1..100
4450

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CDXS's Valuation (28) in the Chemicals Specialty industry is somewhat better than the same rating for VCEL (92) in the Medical Specialties industry. This means that CDXS’s stock grew somewhat faster than VCEL’s over the last 12 months.

VCEL's Profit vs Risk Rating (90) in the Medical Specialties industry is in the same range as CDXS (100) in the Chemicals Specialty industry. This means that VCEL’s stock grew similarly to CDXS’s over the last 12 months.

VCEL's SMR Rating (85) in the Medical Specialties industry is in the same range as CDXS (99) in the Chemicals Specialty industry. This means that VCEL’s stock grew similarly to CDXS’s over the last 12 months.

VCEL's Price Growth Rating (60) in the Medical Specialties industry is in the same range as CDXS (90) in the Chemicals Specialty industry. This means that VCEL’s stock grew similarly to CDXS’s over the last 12 months.

VCEL's P/E Growth Rating (99) in the Medical Specialties industry is in the same range as CDXS (100) in the Chemicals Specialty industry. This means that VCEL’s stock grew similarly to CDXS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CDXSVCEL
RSI
ODDS (%)
Bullish Trend 1 day ago
85%
Bearish Trend 1 day ago
65%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
78%
Momentum
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
75%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
76%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
85%
Bullish Trend 1 day ago
77%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
82%
Bullish Trend 1 day ago
75%
Advances
ODDS (%)
Bullish Trend 14 days ago
82%
Bullish Trend 1 day ago
77%
Declines
ODDS (%)
Bearish Trend 8 days ago
85%
Bearish Trend 8 days ago
74%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
72%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
72%
View a ticker or compare two or three
Interact to see
Advertisement
CDXS
Daily Signal:
Gain/Loss:
VCEL
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MMUIX25.400.37
+1.48%
MFS Utilities I
DBMZX23.130.15
+0.65%
BNY Mellon Sm/Md Cp Gr Z
MDOAX10.89-0.01
-0.09%
Morgan Stanley Developing Opportunity A
WFIVX35.42-0.27
-0.76%
FT Wilshire 5000 Index Invmt
OTCHX24.65-0.33
-1.32%
MFS Mid Cap Growth R3

CDXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CDXS has been loosely correlated with ABCL. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if CDXS jumps, then ABCL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CDXS
1D Price
Change %
CDXS100%
-5.56%
ABCL - CDXS
52%
Loosely correlated
+0.57%
DNLI - CDXS
50%
Loosely correlated
-4.22%
NTLA - CDXS
50%
Loosely correlated
-0.08%
PRAX - CDXS
49%
Loosely correlated
+0.46%
CRSP - CDXS
48%
Loosely correlated
+1.34%
More

VCEL and

Correlation & Price change

A.I.dvisor indicates that over the last year, VCEL has been loosely correlated with VCYT. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if VCEL jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VCEL
1D Price
Change %
VCEL100%
+0.43%
VCYT - VCEL
52%
Loosely correlated
-1.10%
AXON - VCEL
38%
Loosely correlated
-1.89%
MRNA - VCEL
37%
Loosely correlated
-0.82%
CRSP - VCEL
37%
Loosely correlated
+1.34%
CDXS - VCEL
36%
Loosely correlated
-5.56%
More